YLYulia A. Lushpaeva

Yulia A. Lushpaeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yulia A. Lushpaeva has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sleep characterization — a marker of metabolic health: actigraphy data

    by Ju.V. Nelaeva, A.A. Nelaeva, A.A. Vostrikova, I.M. Petrov, E.B. Hramova

    Visceral obesity is a key component of metabolic syndrome and has a significant influence on the reduction of life expectancy. We considered key sleep characteristics recorded by actigraphy as the main risk factors of obesity development. Objective. To study the sleep characteristics and its correlation with metabolic risk progression in subjects with obesity. Materials and methods. A comparative one-time single-center study including women with I degree of obesity (WHO) (n=80) comparable by age — 43.61±2.57 years was carried out. An assessment of anthropometric parameters and lipid metabolism indicators was performed on the basis of multidisciplinary clinic of Tyumen State Medical University. Patients were divided into 2 groups depending on the value of waist circumference/height (WC/height): the 1st group — WC/height<0.6 cm which corresponds to «absence of high metabolic risk», the 2nd group — WC/height ≥0.6 cm that is «high metabolic risk». PSQI (Pittsburgh sleep quality index for the last month) questionnaire of all participants was carried out and actigraphy was performed to assess sleep characteristics. Additionally, the parameters of circadian rhythms of body and wrist skin temperature were evaluated. Melatonin concentration in saliva was examined in all patients using Sunrise Bio-Rad («Bio-Rad Laboratories, Inc.», USA) apparatus. Statistical data processing was conducted using IBM SPSS Statistics, 26.0.0.1 version («IBM Corporation», USA). Results. WC/height index was 0.56±0.02 cm in the 1st group (n=32), while the 2nd group subjects (n=48) had a higher risk — 0.60±0.03 cm, p=0.001. The results of the questionnaire corresponded to the main parameters defined by actigraphy in both groups, however longer wake time after sleep onset (WASO) was in the 2nd group subjects. At the same time, negative correlations between sleep duration and WC increase (r=–0.663, p=0.001), increase of triglyceride (r=–0.378, p=0.001) and low-density lipoproteins (r=–0.245, p=0.001) levels in blood plasma were found. Additional factors confirming circadian desynchronization in the 2nd group subjects were decrease of wrist skin temperature (36.28±0.04 °C) and lower concentration of melatonin level at secretion peak (at 3:00 a.m.) compared to the 1st group subjects (6.27 [2.79; 10.67] pg/ml and 8.70 [5.46; 14.11] pg/ml, respectively). Conclusion. The sleep characteristics studied by us according to the actigraphy data (duration less than 7 hours, reduction of sleep efficiency less than 80%, long episodes of wake time after sleep onset) are the key parameters of «sleep-wake» cycle disorder and along with circadian disorders of body and wrist skin temperature may be early predictors of metabolic abnormalities in women with I degree of obesity.

  • Open Access

    The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)

    by Yu. A. Lushpaeva

    We describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena were observed within 6 months of treatment.

  • Open Access

    Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)

    by I. M. Patrikeeva, Yu. A. Lushpaeva, N. V. Knaub, E. A. Ustinova, O. A. Belikov, M. B. Dolgikh, T. Yu. Malysheva

    The Tyumen Regional Rheumatology Center has gained experience in the use of the interleukin-6 inhibitor olokizumab (OKZ) in the treatment of patients with rheumatoid arthritis (RA).Objective: to evaluate the efficacy and safety of OKZ therapy in patients with RA in real-life clinical practice.Material and methods. The analysis included 75 patients with a confirmed diagnosis of RA who were prescribed OKZ at a dose of 64 mg every 4 weeks. All patients underwent a standard clinical and laboratory examination and concomitant diseases were recorded. The results were evaluated after 1, 6 and 12 months of therapy. A retrospective evaluation of radiological outcomes was performed in 20 patients who had received OKZ for at least 1 year.Results and discussion. After only one month of OKZ treatment, the proportion of patients with high RA activity according to DAS28-CRP decreased statistically significantly from 81% to 53.3%. After 6 months, 55 (73.33%) of 75 patients continued OKZ therapy, and most of them (74.55%) achieved the stage of drug remission, while high RA activity was not detected. After 12 months, 43 (57.33%) of the 75 patients continued OKZ therapy, with low activity and remission observed in 16.2 and 69.8% of them, respectively. During these periods, there was no radiological progression of RA against the background of OKZ therapy. Ten patients (13.33%) discontinued OKZ therapy due to insufficient efficacy, 2 (2.67%) due to pregnancy, 14 (18.67%) due to adverse events and 6 (8%) for other reasons.Conclusion. In real-world clinical practice, OKZ showed significant therapeutic potential and a favorable safety profile in patients with RA.

  • Open Access

    The role of diet in improving fertility in obesity

    by A.A. Vostrikova, Yu.V. Nelaeva, A.A. Nelaeva

    Роль рациона питания в улучшении фертильности при ожирении

  • A patient with osteoarthritis at an outpatient appointment. Unresolved problems

    by Y.A. Lushpaeva

    The purpose of the study was to identify the problems of diagnosis, interdisciplinary interaction and the causes of defects in the treatment of patients with osteoarthritis on an outpatient basis, as well as to assess the efficacy and safety of using the medicine from bioactive concentrate of small marine fish, in routine clinical practice in patients with knee osteoarthritis. The results of an out-patient reception hours with a rheumatologist and case histories of 2312 patients with a referral diagnosis of osteoarthritis of various localization were analyzed. It turned out that 47% of all referrals to a rheumatologist with a referral diagnosis of osteoarthritis can be regarded as unfounded. It was found that 45% of patients, even with an established reliable diagnosis of osteoarthritis, on an outpatient basis, therapy was not prescribed in full and did not comply with the recommendations for the management of this category of patients. After 2 courses (within a year) of treatment with a drug based on a bioactive concentrate of small marine fish, 67% of patients with osteoarthritis of the knee joints were satisfied with the effect of therapy, noting a decrease in pain intensity, an improvement in knee joint function and quality of life. No adverse events were reported in the observation group. Despite the fact that at present the problem of osteoarthritis is well covered, in real clinical practice at the stage of primary care physicians often face difficulties in solving both diagnostic and therapeutic problems. In this regard, there is an urgent need to revise and adapt to the routine outpatient practice of interdisciplinary algorithms for managing patients with osteoarthritis, with the determination of the intervention threshold of a primary care physician and a specialist physician. However, there is a need to develop and introduce into routine clinical practice optimized scales/questionnaires for dynamic assessment of the quality of life of patients with knee osteoarthritis. The study demonstrates a fairly high efficacy, safety and availability of a drug based on a bioactive concentrate of small marine fish, and treatment with this drug can be widely used in the complex therapy of osteoarthritis of the knee joints.


  • Open Access

    Modern insights into ophthalmic manifestations of rheumatic diseases

    by Daria A. Karpova, Ekaterina E. Savina, Maria N. Ponomareva, Yulia A. Lushpaeva, Irina M. Partikeeva

    This literature review is devoted to the analysis of modern insights into ophthalmological manifestations (according to the data of foreign scientific literature in the PubMed system for 20172020) of the most common rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, systemic scleroderma, systemic vasculitis), which are characterized by damage to all structures of the eye and its adnexa: eyelids, orbital tissues, eyeball tunics, vessels, optic nerve and vitreous. Ocular lesion may be an onset, one of the diagnostic signs, or a biomarker of underlying medical condition.